Letter to the Editor
Response: psoriasis treatment should be stratified in order to better assess the cardiovascular event rates
Version of Record online: 7 MAY 2013
© 2013 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 274, Issue 3, page 290, September 2013
How to Cite
Ahlehoff, O. and Hansen, P. R. (2013), Response: psoriasis treatment should be stratified in order to better assess the cardiovascular event rates. Journal of Internal Medicine, 274: 290. doi: 10.1111/joim.12080
- Issue online: 10 AUG 2013
- Version of Record online: 7 MAY 2013
- Accepted manuscript online: 23 APR 2013 02:15AM EST
We greatly appreciate the interest in our recent pharmacoepidemiological study of cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs . We agree with Balta and colleagues that further studies are needed to evaluate the impact on cardiovascular risk of individual systemic antipsoriatic therapies. Also, as mentioned in our report , we fully acknowledge the limitations of our study and the need for large-scale randomized clinical trials to determine the cardiovascular safety and efficacy of individual systemic antipsoriatic drugs. Before such data become available; however, we believe that studies such as ours add considerable weight to the evolving evidence base underlying the perceived benefit/risk ratio of systemic antipsoriatic therapies.
Conflict of interest statement
There is no conflict of interest to declare.